A number of therapies designed to treat patients with lung cancer have been approved this year, including products from Novartis (NYSE:NVS), Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY). That progress is exciting for Dr. Fred Hirsch, the head of the International Association for the Study of Lung Cancer.
“We do have a lot of good things to tell the public these days – that tremendous progress has happened both in terms of early detection, lung cancer screening and foremost, the treatment of patients with advanced lung cancer,” he told Drug Delivery Business News.
The milestones reached by industry and researchers within the last few years are largely rooted in a better understanding of the biology of lung cancer, according to Hirsch, which has translated into the development of personalized therapies for individual patients
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.